Familial Amyloid Polyneuropathy
📧 Sign up to get email alerts when something new happens for Familial Amyloid Polyneuropathy.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-27EMA Authorised: Wainzua (eplontersen sodium) — AstraZeneca AB
The European Medicines Agency authorised Wainzua (eplontersen sodium) from AstraZeneca AB for familial amyloid polyneuropathy.
-
EMA approval · 2025-12-19EMA Authorised: Attrogy (diflunisal) — Purpose Pharma International AB
The EMA has authorised Attrogy (diflunisal) by Purpose Pharma International AB for familial amyloid polyneuropathy, marking EU marketing aut…
-
FDA approval · 2019-05-03FDA Approved: VYNDAQEL — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved VYNDAQEL (tafamidis meglumine) as the original application for the treatment of transthyretin-related familial amyloid polyneur…